Product Description
NVD-001 is Novadips first generation autologous cell-based osteogenic (bone healing) product derived from the Companys proprietary tissue regeneration platform.
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novadip Biosciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Spondylolisthesis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Spine1 | P2 |
Completed |
Spondylolisthesis |
2021-01-01 |
24% |
| NVD-001 Spine1 | P2 |
Completed |
Spondylolisthesis |
2020-12-09 |